ArticleMedical hypotheses2011
Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.
Article in Medical hypotheses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01255215 (Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Methemoglobin and nitric oxide therapy in Ugandan children hospitalized for febrile illness: results from a prospective cohort study and randomized double-blind placebo-controlled trial.BMC pediatrics · 2016Trial
- Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial.Malaria journal · 2015Trial
- Use of a three-band HRP2/pLDH combination rapid diagnostic test increases diagnostic specificity for falciparum malaria in Ugandan children.Malaria journal · 2014Trial
- Neurovascular Pathophysiology and Emerging Biomarkers in Cerebral Malaria: An Integrative Perspective.Neurology international · 2025Review
- Oxidative Stress in Malaria: Potential Benefits of Antioxidant Therapy.International journal of molecular sciences · 2022Review
- Nitric oxide: Clinical applications in critically ill patients.Nitric oxide : biology and chemistry · 2022Review
- Inhaled nitric oxide.British journal of pharmacology · 2019Review
- Severe malaria: what's new on the pathogenesis front?International journal for parasitology · 2017Review
- The evidence for a role of vasospasm in the pathogenesis of cerebral malaria.Malaria journal · 2015Review
- Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.PLoS pathogens · 2014Article
- Performance of point-of-care diagnostics for glucose, lactate, and hemoglobin in the management of severe malaria in a resource-constrained hospital in Uganda.The American journal of tropical medicine and hygiene · 2014Article
- Experimental Models of Microvascular Immunopathology: The Example of Cerebral Malaria.Journal of neuroinfectious diseases · 2014Article
- Fatal cerebral malaria: a venous efflux problem.Frontiers in cellular and infection microbiology · 2014Review
- Contrasting pediatric and adult cerebral malaria: the role of the endothelial barrier.Virulence · 2013Review
- Article
- Oxidative stress in malaria.International journal of molecular sciences · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
Abstract
We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.